Pharmaceutical Marketing Congress Release: Centers For Medicaid And Medicare Services -CMS- And Fortune 20 Pharmaceutical Companies Discuss Greater Emphasis On Evidence-Based Drugs As A Result Of Medicare Part D And Reimbursement Changes

NEW YORK--(BUSINESS WIRE)--June 2, 2005--On September 12-14, the world’s original and largest gathering of pharmaceutical marketers and sales professionals will hear how certain therapeutic categories will grow due to Medicare Part D legislation. “Brand marketers should be looking at their messaging beyond pricing and contracting and reposition their clinical profile now to stay competitive,” says Heej Ko, VP of Conference Programming, Pharmaceutical Marketing Congress.